Stagezero Life Sciences Stock Performance
| SZLS Stock | CAD 0.04 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and StageZero Life are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days StageZero Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, StageZero Life is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:8 | Dividend Date 2020-09-18 | Last Split Date 2020-09-18 |
1 | StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com | 09/30/2024 |
| Begin Period Cash Flow | 33.3 K |
StageZero |
StageZero Life Relative Risk vs. Return Landscape
If you would invest 4.00 in StageZero Life Sciences on September 3, 2024 and sell it today you would earn a total of 0.00 from holding StageZero Life Sciences or generate 0.0% return on investment over 90 days. StageZero Life Sciences is generating negative expected returns and assumes 0.0% volatility on return distribution over the 90 days horizon. Simply put, 0% of stocks are less volatile than StageZero, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
StageZero Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for StageZero Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as StageZero Life Sciences, and traders can use it to determine the average amount a StageZero Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SZLS |
Based on monthly moving average StageZero Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of StageZero Life by adding StageZero Life to a well-diversified portfolio.
StageZero Life Fundamentals Growth
StageZero Stock prices reflect investors' perceptions of the future prospects and financial health of StageZero Life, and StageZero Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on StageZero Stock performance.
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 6.71 M | ||||
| Shares Outstanding | 123.55 M | ||||
| Price To Book | 5.94 X | ||||
| Price To Sales | 1.70 X | ||||
| Revenue | 2.88 M | ||||
| Gross Profit | 1.18 M | ||||
| EBITDA | (4.46 M) | ||||
| Net Income | (12.53 M) | ||||
| Cash And Equivalents | 754.87 K | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.18 X | ||||
| Book Value Per Share | (0.08) X | ||||
| Cash Flow From Operations | (809.15 K) | ||||
| Earnings Per Share | (0.16) X | ||||
| Market Capitalization | 4.94 M | ||||
| Total Asset | 700.65 K | ||||
| Retained Earnings | (123.04 M) | ||||
| Working Capital | (6.76 M) | ||||
About StageZero Life Performance
By examining StageZero Life's fundamental ratios, stakeholders can obtain critical insights into StageZero Life's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that StageZero Life is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.48 | 7.11 | |
| Return On Tangible Assets | (18.74) | (17.80) | |
| Return On Capital Employed | 1.10 | 1.16 | |
| Return On Assets | (18.74) | (17.80) | |
| Return On Equity | 1.37 | 1.44 |
Things to note about StageZero Life Sciences performance evaluation
Checking the ongoing alerts about StageZero Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for StageZero Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| StageZero Life generated a negative expected return over the last 90 days | |
| StageZero Life has some characteristics of a very speculative penny stock | |
| StageZero Life has high likelihood to experience some financial distress in the next 2 years | |
| StageZero Life Sciences has accumulated 1.8 M in total debt. StageZero Life Sciences has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist StageZero Life until it has trouble settling it off, either with new capital or with free cash flow. So, StageZero Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like StageZero Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for StageZero to invest in growth at high rates of return. When we think about StageZero Life's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.88 M. Net Loss for the year was (12.53 M) with profit before overhead, payroll, taxes, and interest of 1.18 M. | |
| StageZero Life Sciences has accumulated about 754.87 K in cash with (809.15 K) of positive cash flow from operations. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing StageZero Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether StageZero Life's stock is overvalued or undervalued compared to its peers.
- Examining StageZero Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating StageZero Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of StageZero Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of StageZero Life's stock. These opinions can provide insight into StageZero Life's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in StageZero Stock
StageZero Life financial ratios help investors to determine whether StageZero Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in StageZero with respect to the benefits of owning StageZero Life security.